PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors | MicrobiomeTrials← Back to trialsNCT06721689
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-03-23Est. Completion: 2030-04
Enrollment target: 59 participants Locations- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Texas Children's Hospital, Houston, Texas, United States
- University of Utah Hospital, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in
Advanced Solid TumorTNBC - Triple-Negative Breast CancerGastric CancerLeukemia Acute Myeloid Leukemia (AML)
This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating int…
New Haven, United StatesEst. completion Dec 24, 2026
Extensive-Stage Small Cell Lung CancerExtrapulmonary Neuroendocrine CarcinomaRecurrent or RefractorySolid Tumors
Background:
Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (E…
Bethesda, United StatesEst. completion Jan 30, 2030
Locally Advanced Gastrointestinal Stromal TumorMetastatic Gastrointestinal Stromal TumorRecurrent Gastrointestinal Stromal TumorRefractory Malignant Gastrointestinal Stromal TumorUnresectable Malignant Gastrointestinal Stromal Tumor
This phase II trial tests the effect of autologous tumor infiltrating lymphocytes (TILs) in combination with interleukin…
Columbus, United StatesEst. completion Dec 31, 2027